Suppr超能文献

可注射治疗性肽——再生医学和运动表现的辅助手段?

Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?

作者信息

DeFoor Mikalyn T, Dekker Travis J

机构信息

San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, U.S.A.

10th Medical Group, US Air Force Academy, San Antonio, Colorado, U.S.A.

出版信息

Arthroscopy. 2025 Feb;41(2):150-152. doi: 10.1016/j.arthro.2024.09.005. Epub 2024 Sep 10.

Abstract

High-level athletes and bodybuilders are constantly seeking novel therapies to enhance recovery and expedite return from injury-injectable peptides are a new and trending therapy that may be the wave of the future in the realm of regenerative medicine research in treating joint injuries and osteoarthritis. Very early in vivo research on pharmacokinetics indicates the possibility that body protection compound 157 (BPC-157) is at the forefront of therapeutic peptides, with early demonstrations of this experimental peptide optimizing endurance training, metabolism, recovery, and tissue repair. Although unregulated and yet readily available for purchase over the internet, there is scarce orthopaedic literature investigating the clinical use and outcomes of such therapeutic peptides in tendon, muscle, and cartilage injury. However, this has not slowed the recent exponential growth of the multi-billion-dollar industry in the development of therapeutic peptides. As orthopaedic surgeons and team physicians, we should stay up to date with the latest pharmacokinetic, safety, ethical, and legal profiles and regulations regarding synthetic peptide supplementation for injury recovery and sports performance optimization in our patients, from elite athletes to fitness fanatics, because they will continue to seek the latest and greatest in treatment options and will be approaching us with questions on their results, risks, and benefits.

摘要

高水平运动员和健美运动员一直在寻找新的疗法来促进恢复并加速伤病康复——可注射肽是一种新兴且流行的疗法,可能是未来再生医学研究领域治疗关节损伤和骨关节炎的潮流。关于药代动力学的极早期体内研究表明,身体保护化合物157(BPC - 157)有可能处于治疗性肽的前沿,早期研究已证明这种实验性肽可优化耐力训练、新陈代谢、恢复和组织修复。尽管此类肽不受监管且可在网上轻易买到,但骨科文献中很少有研究调查这类治疗性肽在肌腱、肌肉和软骨损伤中的临床应用及效果。然而,这并未减缓治疗性肽数十亿美元产业近期的指数级增长。作为骨科医生和队医,我们应该紧跟最新的药代动力学、安全性、伦理和法律情况以及关于合成肽补充剂用于患者(从精英运动员到健身爱好者)伤病恢复和运动表现优化的相关规定,因为他们会继续寻求最新、最好的治疗选择,并就其效果、风险和益处向我们提问。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验